Paraskevi Panagopoulou1, Sonia Alexiadou2, Maria Ntoumpara1, Anna Papazoglou2, Alexandros Makis3, Athanasios Tragiannidis4, Maria Fotoulaki1, Elpis Mantadakis5. 1. 4th Department of Pediatrics, Papageorgiou General Hospital, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. 2. Department of Pediatrics, Faculty of Medicine, Democritus University of Thrace, 6th Kilometer Alexandroupolis-Makris, 68 100, Alexandroupolis, Thrace, Greece. 3. Department of Pediatrics, Faculty of Medicine, University of Ioannina, Ioannina, Greece. 4. 2nd Department of Pediatrics, AHEPA University Hospital, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. 5. Department of Pediatrics, Faculty of Medicine, Democritus University of Thrace, 6th Kilometer Alexandroupolis-Makris, 68 100, Alexandroupolis, Thrace, Greece. emantada@med.duth.gr.
Abstract
BACKGROUND: Parenteral iron is generally considered safe in adults, and severe adverse events are extremely rare. Ferric carboxymaltose (FCM), a third-generation parenteral iron product, is not licensed for pediatric use. OBJECTIVE: The aim of this study was to present our data on the safety of FCM in children with iron deficiency (ID) and/or iron deficiency anemia (IDA) and to investigate through a systematic literature review articles reporting on the safety of FCM use in children with ID/IDA. PATIENTS AND METHODS: Safety data regarding children treated with FCM for ID/IDA from four pediatric departments in Greece over a 26-month period are presented. Additionally, a literature search was performed in PubMed, Scopus, and Google Scholar on December 4, 2021 for articles reporting on the use of FCM in children with ID/IDA. Review articles, guidelines, case reports/case series, and reports on the use of FCM for conditions other than ID/IDA were excluded. Identified articles were screened for all reported adverse events (AE) that were graded according to the Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: In our cohort, 37 children with ID/IDA received 41 FCM infusions. All infusions were tolerated well. In addition, 11 articles reporting 1231 infusions of FCM in 866 children were identified in the literature. Among them, 52 (6%) children developed AE that were graded as mild or moderate (grades I-III). CONCLUSIONS: Our patient cohort and this literature review provide further evidence for the good safety profile of FCM in children, although well-designed prospective clinical trials with appropriate safety endpoints are still required.
BACKGROUND: Parenteral iron is generally considered safe in adults, and severe adverse events are extremely rare. Ferric carboxymaltose (FCM), a third-generation parenteral iron product, is not licensed for pediatric use. OBJECTIVE: The aim of this study was to present our data on the safety of FCM in children with iron deficiency (ID) and/or iron deficiency anemia (IDA) and to investigate through a systematic literature review articles reporting on the safety of FCM use in children with ID/IDA. PATIENTS AND METHODS: Safety data regarding children treated with FCM for ID/IDA from four pediatric departments in Greece over a 26-month period are presented. Additionally, a literature search was performed in PubMed, Scopus, and Google Scholar on December 4, 2021 for articles reporting on the use of FCM in children with ID/IDA. Review articles, guidelines, case reports/case series, and reports on the use of FCM for conditions other than ID/IDA were excluded. Identified articles were screened for all reported adverse events (AE) that were graded according to the Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: In our cohort, 37 children with ID/IDA received 41 FCM infusions. All infusions were tolerated well. In addition, 11 articles reporting 1231 infusions of FCM in 866 children were identified in the literature. Among them, 52 (6%) children developed AE that were graded as mild or moderate (grades I-III). CONCLUSIONS: Our patient cohort and this literature review provide further evidence for the good safety profile of FCM in children, although well-designed prospective clinical trials with appropriate safety endpoints are still required.
Authors: James R Goodhand; Nikolasos Kamperidis; Arati Rao; Faiden Laskaratos; Adam McDermott; Mahmood Wahed; Sandhia Naik; Nick M Croft; James O Lindsay; Ian R Sanderson; David S Rampton Journal: Inflamm Bowel Dis Date: 2011-05-20 Impact factor: 5.325
Authors: Axel U Dignass; Christoph Gasche; Dominik Bettenworth; Gunnar Birgegård; Silvio Danese; Javier P Gisbert; Fernando Gomollon; Tariq Iqbal; Konstantinos Katsanos; Ioannis Koutroubakis; Fernando Magro; Guillaume Savoye; Jürgen Stein; Stephan Vavricka Journal: J Crohns Colitis Date: 2014-12-03 Impact factor: 9.071
Authors: Natalie Filmann; Julia Rey; Sven Schneeweiss; Sandro Ardizzone; Palle Bager; Gaetano Bergamaschi; Ioannis Koutroubakis; Stefan Lindgren; Felipe de la Morena; Bjørn Moum; Stephan R Vavricka; Oliver Schröder; Eva Herrmann; Irina Blumenstein Journal: Inflamm Bowel Dis Date: 2014-05 Impact factor: 5.325